Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide

US11304914B2 · kind B2 · utility

Assignee

• PTC THERAPEUTICS, INC. · US

Inventors

• Paul Mollard · Domène, FR
• Peter Giannousis · Mountain View, US
• Shazad Suchit · Devens, US
• Mahmoud Mirmehrabi · Halifax, CA

Key dates

• Filing date: Jul 1, 2020
• Grant date: Apr 19, 2022
• Expiry date: Jul 1, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2601/16
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed herein are polymorphic and amorphous forms of anhydrate, hydrate, and solvates of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide and methods of using such compositions for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging. Further disclosed are methods of making such polymorphic and amorphous forms.